A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2004
11/16/2004	US6818447 Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
11/16/2004	US6818445 Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
11/16/2004	US6818439 Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
11/16/2004	US6818422 For preventing/treating human arteriosclerosis by inhibiting generation of foamy macrophage
11/16/2004	US6818419 IRAK-4: compositions and methods of use
11/16/2004	US6818412 For diagnosis and therapy
11/16/2004	US6818407 Microbiocidal peptide for use in the treatment of respiratory system disorders
11/16/2004	US6818405 Diagnosis and treatment of osteoporosis; obtain humans, administer modulator, monitor response to modulator
11/16/2004	US6818233 Dietary supplements containing natural ingredients
11/16/2004	US6818230 Antiproliferative effect can be achieved by subjecting conditioned medium obtained by culturing the structures of the invention in culture medium to filtration; anticancer agents
11/16/2004	US6818224 Using fluid pharmaceutical which allows the controlled release of at least one active substance and which comprises active substance, phospholipid, solvent, fatty acid and can form gel instantaneously for therapy of periodontitis
11/16/2004	US6818220 Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
11/16/2004	US6818218 Prevention and treatment of amyloidogenic disease
11/16/2004	US6818217 Immunoreactive peptides
11/16/2004	US6818215 Antibodies to senescent cell-derived inhibiters of DNA synthesis
11/16/2004	US6818214 Modulating cell proliferation or apoptosis comprising modulating psoriastatin activity
11/16/2004	CA2159109C Therapeutic uses of keratinocyte growth factor
11/16/2004	CA2145383C O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
11/16/2004	CA2074719C Calcium channel compositions and methods
11/16/2004	CA2059692C Pneumoccoccal polysaccharide conjugate vaccine
11/16/2004	CA2030988C Pharmaceutical for subcutaneous or intramuscular administration containing polypeptides
11/11/2004	WO2004097421A2 Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
11/11/2004	WO2004097420A1 Method for the detection of a neurological dementia disease associated with a loss of short or long term memory, corresponding prosaas peptide and detection reagents
11/11/2004	WO2004097405A2 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor h7tba62 (h7tba62)
11/11/2004	WO2004097047A1 Mutations in the human pcsk9 gene associated to hypercholesterolemia
11/11/2004	WO2004097034A2 Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 4 (tmprss4)
11/11/2004	WO2004097022A1 Catalyst for sugar chain cleavage
11/11/2004	WO2004097020A2 Rna interference mediated inhibition of map kinase gene expression
11/11/2004	WO2004096976A2 Spex compositions and methods of use
11/11/2004	WO2004096859A1 Chaperonine-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure of target protein, sustained-release preparation and method of producing antibody against target protein
11/11/2004	WO2004096856A2 Secreted protein family
11/11/2004	WO2004096854A2 Insulin analogs having protracted time action
11/11/2004	WO2004096853A1 Combined use of keratinocyte growth factor agonists and gastrin compounds
11/11/2004	WO2004096852A1 A RECOMBINANT HUMAN INTERFERON ϖ, THE METHOD FOR EXPRESSING IT AND THE USES OF IT
11/11/2004	WO2004096851A1 Galectin 9-inducing factor
11/11/2004	WO2004096850A1 Method for the production of an n-terminally modified chemotactic factor
11/11/2004	WO2004096846A2 Nogo-b, a regulator of endothelial cell function and vessel remodeling
11/11/2004	WO2004096845A2 Beta-amyloid inhibitors and use thereof
11/11/2004	WO2004096844A2 Group 1 mite polypeptide variants
11/11/2004	WO2004096843A1 Polypeptide capable of assisting digestive organ absorption
11/11/2004	WO2004096841A1 Glut-1 as a receptor for htlv envelopes and its uses
11/11/2004	WO2004096840A1 Template- fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
11/11/2004	WO2004096839A1 Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
11/11/2004	WO2004096837A1 Vitamin c derivatives with peptide, preparation method thereof and composition comprising the same
11/11/2004	WO2004096835A1 Nematode pppt-like sequences
11/11/2004	WO2004096834A1 Extraction process for a pharmaceutical product
11/11/2004	WO2004096832A2 Novel antiangiogenic peptides
11/11/2004	WO2004096826A2 Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna)
11/11/2004	WO2004096368A1 Treatment of hi-virus infections with oxidised blood proteins
11/11/2004	WO2004096291A1 In vivo imaging using peptide derivatives
11/11/2004	WO2004096290A1 Biological pacemaker
11/11/2004	WO2004096289A1 Gene introduction efficiency enhancer
11/11/2004	WO2004096275A1 Instrument for inducing cytokine and method of inducing cytokine
11/11/2004	WO2004096269A2 Botulinum neurotoxin for treating tics and obsessive compulsive behaviors
11/11/2004	WO2004096268A2 Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
11/11/2004	WO2004096267A1 Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
11/11/2004	WO2004096266A1 Improved physical stability of insulin formulations
11/11/2004	WO2004096265A1 Nutrient liquid containing human growth hormone and the preparation method thereof
11/11/2004	WO2004096264A1 Method for treating infection with feline leukemia virus
11/11/2004	WO2004096263A2 Human serum albumin-free stabilized interferon liquid formulations
11/11/2004	WO2004096262A1 Method of preparing a medicament for anti-tumour therapy involving neutrophils (neutrophil therapy)
11/11/2004	WO2004096261A1 Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
11/11/2004	WO2004096260A1 Preventives or remedies for hepatopathy
11/11/2004	WO2004096259A1 Methods and compositions using gonadotropin hormone releasing hormone
11/11/2004	WO2004096258A1 Compositions and methods for treatment of psoriasis
11/11/2004	WO2004096257A2 Genetic modification of targeted regions of the cardiac conduction system
11/11/2004	WO2004096254A2 Transferrin conjugates for tumor treatment
11/11/2004	WO2004096253A1 Use of inhibitors and antisense oligonucleotides of btk for treating proliferative mastocytosis
11/11/2004	WO2004096247A1 Instrument for inducing cytokine and method of inducing cytokine
11/11/2004	WO2004096241A1 Hmpv treatment with ribavirin and anti-hmpv antibody
11/11/2004	WO2004096239A1 Method for administration of troxacitabine
11/11/2004	WO2004096217A1 Use of n-type calcium channel inhibitors in treating demyelinating diseases
11/11/2004	WO2004096192A1 Fast dissolving orally consumable films containing a sucralose as a sweetener
11/11/2004	WO2004096183A1 Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
11/11/2004	WO2004096181A2 Solid dosage form comprising desmopressin
11/11/2004	WO2004096179A1 Zinc-containing sustained-release composition, its preparation, and method for producing the same
11/11/2004	WO2004096176A2 Solid drug formulation and device for storage and controlled delivery thereof
11/11/2004	WO2004096174A1 Fast dissolving orally consumable films containing pharmaceutically active agents
11/11/2004	WO2004096172A2 Vector for oral administration
11/11/2004	WO2004096161A2 Pharmaceutical compositions for treating painful neuropathy and methods of treating same
11/11/2004	WO2004096159A2 Saposin c-dops: a novel anti-tumor agent
11/11/2004	WO2004096151A2 Methods and devices for the sustained release of multiple drugs
11/11/2004	WO2004096144A2 Compositions and methods for induction of opioid receptors
11/11/2004	WO2004096143A2 Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility
11/11/2004	WO2004096133A2 Method for inhibiting cellular activation by insulin-like growth factor-1
11/11/2004	WO2004096125A2 Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
11/11/2004	WO2004096118A2 Composition for improving cognition and memory
11/11/2004	WO2004096117A2 Drug delivery systems comprising transferrin-nucleic acid conjugates
11/11/2004	WO2004083430A3 SHORT INTERFERING RNA (siRNA) ANALOGUES
11/11/2004	WO2004083231A3 Use of peptide ligands for plasma membrane receptors or similar for mitochondrial activity modulation
11/11/2004	WO2004080482A3 Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure
11/11/2004	WO2004080477A8 Aplidine for multiple myeloma treatment
11/11/2004	WO2004075720A3 Use of intraputaminal infused glial cell-line derived neurotrophic factor in the treatment of parkinson’s disease in humans
11/11/2004	WO2004073684A3 Lipophilic drug delivery vehicle and methods of use thereof
11/11/2004	WO2004073614A3 Combination therapy for the treatment of immunoinflammatory disorders
11/11/2004	WO2004071517A3 Uses of il-23 related reagents
11/11/2004	WO2004069858A3 Leukocyte stimulating peptides
11/11/2004	WO2004069274A3 Sensitizing cells for apoptosis by selectively blocking cytokines
11/11/2004	WO2004066963A3 N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
11/11/2004	WO2004064750A3 Improved constructs for expressing lysosomal polypeptides

1 ... 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 ... 3163